Leerink Partners Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $27
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Leerink Partners analyst Andrew Berens maintains BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and lowers the price target from $39 to $27.
Leerink Partners analyst Andrew Berens maintains BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and lowers the price target from $39 to $27.